News Earnings Beryl Drugs Limited Reports Q3 FY26 Net Loss of ₹16.77 Lacs Amid Manufacturing ChallengesBeryl Drugs Limited Reports Q3 FY26 Net Loss of ₹16.77 Lacs Amid Manufacturing Challenges
Beryl Drugs Limited reported a net loss of ₹16.77 lacs in Q3 FY26 versus a profit of ₹5.22 lacs in Q3 FY25, with revenue declining 28.87% to ₹377.68 lacs. The pharmaceutical company faced operational disruptions due to manufacturing facility suspension from February to November 2025 following FDA directions. Operations resumed on November 28, 2025, after regulatory compliance, positioning the company for potential recovery in subsequent quarters.
*this image is generated using AI for illustrative purposes only.
Beryl Drugs Limited has reported challenging financial results for the third quarter of fiscal year 2026, posting a net loss of ₹16.77 lacs compared to a profit of ₹5.22 lacs in the same quarter of the previous year. The pharmaceutical company's performance was significantly impacted by operational disruptions and declining revenue during the quarter ended December 31, 2025.
Financial Performance Overview
The company's financial metrics showed a marked deterioration across key parameters during Q3 FY26:
| Metric | Q3 FY26 | Q3 FY25 | Change (%) |
|---|---|---|---|
| Revenue from Operations | ₹377.68 lacs | ₹530.93 lacs | -28.87% |
| Total Income | ₹385.04 lacs | ₹540.27 lacs | -28.73% |
| Total Expenses | ₹445.82 lacs | ₹524.22 lacs | -14.95% |
| Profit Before Tax | ₹-60.78 lacs | ₹16.05 lacs | -478.69% |
| Net Profit After Tax | ₹-16.77 lacs | ₹5.22 lacs | -421.26% |
Operational Challenges and Recovery
A significant factor affecting the company's performance was the suspension of part of its manufacturing facility. The facility was suspended with effect from February 11, 2025, following directions issued by the State Food and Drugs Administration (FDA) for upgradation purposes.
The company responded proactively by submitting a comprehensive point-wise rectification and compliance report along with supporting documents and photographs. Following regulatory review, the State Food and Drugs Administration permitted continuation of operations of the concerned section with effect from November 28, 2025, lifting the suspension.
Cost Structure Analysis
Despite the revenue decline, the company managed to reduce several cost components:
| Expense Category | Q3 FY26 | Q3 FY25 | Change |
|---|---|---|---|
| Cost of Materials Consumed | ₹208.19 lacs | ₹262.77 lacs | -₹54.58 lacs |
| Employee Benefits | ₹78.91 lacs | ₹62.01 lacs | +₹16.90 lacs |
| Finance Costs | ₹9.17 lacs | ₹12.04 lacs | -₹2.87 lacs |
| Other Expenses | ₹122.25 lacs | ₹235.55 lacs | -₹113.30 lacs |
Year-to-Date Performance
The nine-month performance for the period ended December 31, 2025, also reflected challenges, with the company reporting a net loss of ₹13.77 lacs compared to a profit of ₹42.70 lacs in the corresponding period of the previous year. Year-to-date revenue declined to ₹1,369.11 lacs from ₹1,717.26 lacs in the previous year.
Earnings Per Share Impact
The financial performance translated into negative earnings per share, with both basic and diluted EPS at ₹-0.33 for Q3 FY26, compared to positive ₹0.10 in Q3 FY25. The company maintained its paid-up equity share capital at ₹507.17 lacs with a face value of ₹10.00 per share.
Regulatory Compliance and Outlook
The company's financial results were prepared in accordance with Indian Accounting Standards and were subject to limited review by statutory auditors. The Board of Directors approved these unaudited financial results in their meeting held on February 9, 2026, ensuring compliance with SEBI listing regulations. With the manufacturing facility suspension now lifted and operations resumed, the company appears positioned to address the operational challenges that impacted its Q3 FY26 performance.
Historical Stock Returns for Beryl Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.23% | -1.85% | -5.24% | -0.09% | -21.63% | +214.49% |
18
